The serum BA levels correlated with the disease severity in NAFLD, whereas the adiponectin levels were inversely correlated [57], supporting that treatment with FXR agonists and/or adiponectin activators may be of help for the prevention of NASH. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.